The US National Security Commission on Emerging Biotechnology (NSCEB) has released a new assessment of the state of the US-China biotechnology competition. This is the latest in a series of new analyses following the publication of its major report and Action Plan for Congress in April 2025. In April, the Commission came to a sobering conclusion: US policymakers have a three-year window to retain, or in some cases regain, biotechnology leadership or risk ceding profound military, geopolitical, and economic advantages to China. Since then, the trajectory the Commission identified has continued – and in several areas intensified. The NSCEB assesses that China is beginning to outpace the U.S. in certain domains of biopharmaceutical innovation, undermining our national and economic security, and global technological leadership.

Full report : Urgent action needed to maintain US global leadership over China in biotech innovation.